Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial

European Journal of Cancer

Volumn 50, Issue 13, 2014, Pages 2190-2200

  Fontein, Duveken B Y ^a   Charehbili, Ayoub ^a   Nortier, Johan W R ^a   Meershoek Klein Kranenbarg, Elma ^a   Kroep, Judith R ^a   Putter, H ^a   Van Riet, Yvonne ^b   Nieuwenhuijzen, Grard A P ^b   De Valk, Bart ^c,d   Terwogt, Jetske M Meerum ^d   Algie, Gijs D ^d   Liefers, Gerrit Jan ^a   Linn, Sabine ^e,f   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c Department of Orthopaedic Surgery   (Netherlands)

^d Department of Surgery Catharina Ziekenhuis ^*  (Netherlands)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast cancer; Breast conserving surgery; Endocrine therapy; Exemestane; Neoadjuvant; Postmenopausal; Pre operative

Indexed keywords

ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; BIOSYNTHESIS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTMENOPAUSE; RECEPTORS, ESTROGEN; SENTINEL LYMPH NODE BIOPSY;

EID: 84905121819     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.05.010     Document Type: Article

References (34)

1. H. Takei, M. Kurosumi, T. Yoshida, Y. Hayashi, T. Higuchi, and S. Uchida et al. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? Breast Cancer 18 2 2011 85 91
2. A. Charehbili, D.B. Fontein, J.R. Kroep, G.J. Liefers, J.S. Mieog, and J.W. Nortier et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review Cancer Treat Rev 40 1 2014 86 92
3. R. Peto, C. Davies, J. Godwin, R. Gray, H.C. Pan, and M. Clarke et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 9814 2012 432 444
4. M. Colleoni, G. Viale, D. Zahrieh, G. Pruneri, O. Gentilini, and P. Veronesi et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 19 2004 6622 6628
5. M. Colleoni, G. Viale, D. Zahrieh, L. Bottiglieri, R.D. Gelber, and P. Veronesi et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy Ann Oncol 19 3 2008 465 472
6. M. Colleoni, V. Bagnardi, N. Rotmensz, R.D. Gelber, G. Viale, and G. Pruneri et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy Breast Cancer Res Treat 116 2 2009 359 369
7. A. Frassoldati, M. Maur, V. Guarneri, M. Nicolini, and P.F. Conte Predictive value of biologic parameters for primary chemotherapy in operable breast cancer Clin Breast Cancer 6 4 2005 315 324
8. A. Goldhirsch, E.P. Winer, A.S. Coates, R.D. Gelber, M. Piccart-Gebhart, and B. Thurlimann et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 24 9 2013 2206 2223
9. J.M. Dixon, L. Renshaw, E.J. Macaskill, O. Young, J. Murray, and D. Cameron et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole Breast Cancer Res Treat 113 1 2009 145 151
10. M.J. Ellis Neoadjuvant endocrine therapy for breast cancer: more questions than answers J Clin Oncol 23 22 2005 4842 4844
11. N. Harbeck, C. Thomssen, and M. Gnant St. Gallen 2013: brief preliminary summary of the consensus discussion Breast Care (Basel) 8 2 2013 102 109
12. J. Mathew, K.S. Asgeirsson, L.R. Jackson, K.L. Cheung, and J.F. Robertson Neoadjuvant endocrine treatment in primary breast cancer - review of literature Breast 18 6 2009 339 344
13. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
14. V.F. Semiglazov, V.V. Semiglazov, G.A. Dashyan, E.K. Ziltsova, V.G. Ivanov, and A.A. Bozhok et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 2 2007 244 254
15. E. Alba, L. Calvo, J. Albanell, J.R. De la Haba, L.A. Arcusa, and J.I. Chacon et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study Ann Oncol 23 12 2012 3069 3074
16. G. von Minckwitz, J.U. Blohmer, S.D. Costa, C. Denkert, H. Eidtmann, and W. Eiermann et al. Response-guided neoadjuvant chemotherapy for breast cancer J Clin Oncol 31 29 2013 3623 3630
17. W. Eiermann, S. Paepke, J. Appfelstaedt, A. Llombart-Cussac, J. Eremin, and J. Vinholes et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 11 2001 1527 1532
18. L. Cataliotti, A.U. Buzdar, S. Noguchi, J. Bines, Y. Takatsuka, and K. Petrakova et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial Cancer 106 10 2006 2095 2103
19. I.E. Smith, M. Dowsett, S.R. Ebbs, J.M. Dixon, A. Skene, and J.U. Blohmer et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 22 2005 5108 5116
20. A. Llombart-Cussac, A. Guerrero, A. Galan, V. Caranana, E. Buch, and A. Rodriguez-Lescure et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer Clin Transl Oncol 14 2 2012 125 131
21. U.E. Krainick-Strobel, W. Lichtenegger, D. Wallwiener, A.H. Tulusan, F. Janicke, and G. Bastert et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy BMC Cancer 8 2008 62
22. R. Carpenter, J.C. Doughty, C. Cordiner, N. Moss, A. Gandhi, and C. Wilson et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery Breast Cancer Res Treat 2014
23. H. Ojeda-Fournier, G.J. de, and N. Hylton Breast magnetic resonance imaging for monitoring response to therapy Magn Reson Imaging Clin N Am 21 3 2013 533 546
24. N.M. Hylton, J.D. Blume, W.K. Bernreuter, E.D. Pisano, M.A. Rosen, and E.A. Morris et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - results from ACRIN 6657/I-SPY TRIAL Radiology 263 3 2012 663 672
25. Dutch national breast cancer guidelines. 2011. 1-12-2011. Ref Type: Online Source.
26. M.J. Ellis, V.J. Suman, J. Hoog, L. Lin, J. Snider, and A. Prat et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031 J Clin Oncol 29 17 2011 2342 2349
27. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial J Natl Cancer Inst 94 14 2002 1054 1065
28. W. van de Water, D.B. Fontein, J.G. van Nes, J.M. Bartlett, E.T. Hille, and H. Putter et al. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis Eur J Cancer 49 2 2013 297 304
29. A. Goldhirsch, J.N. Ingle, R.D. Gelber, A.S. Coates, B. Thurlimann, and H.J. Senn Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 8 2009 1319 1329
30. J.M. Harvey, G.M. Clark, C.K. Osborne, and D.C. Allred Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 5 1999 1474 1481
31. T. Petit, M. Wilt, M. Velten, J.F. Rodier, J.P. Fricker, and P. Dufour et al. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer Breast Cancer Res Treat 124 2 2010 387 391
32. H.J. Burstein Preoperative therapy as a model for translational research in breast cancer Cancer Invest 26 3 2008 217 221
33. M. Dowsett, I.E. Smith, S.R. Ebbs, J.M. Dixon, A. Skene, and R. A'Hern et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 2 2007 167 170
34. Ellis MJ, Suman V, McCall L, et al. Z1031B neoadjuvant aromatase inhibitor trial: a phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level <10%. Cancer Res 2012;17:PD07-01.